Get the Stockscreener App
18.92
1.34%
0.25
After Hours:
18.96
0.04
+0.21%
Denali Therapeutics Inc stock is traded at $18.92, with a volume of 2.51M.
It is up +1.34% in the last 24 hours and down -8.38% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
See More
Previous Close:
$18.67
Open:
$18.99
24h Volume:
2.51M
Relative Volume:
1.46
Market Cap:
$3.00B
Revenue:
$1.27M
Net Income/Loss:
$-512.54M
P/E Ratio:
-6.3723
EPS:
-2.9691
Net Cash Flow:
$-422.10M
1W Performance:
-5.68%
1M Performance:
-8.38%
6M Performance:
+27.07%
1Y Performance:
+18.32%
1-Day Range:
$18.33
$19.40
1-Week Range:
$18.10
$20.17
52-Week Range:
$12.58
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
18.92 | 2.96B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval - The Motley Fool
MSN Money - MSN
Assessing Denali Therapeutics (DNLI) Valuation After Takeda Ends DNL593 Partnership - Sahm
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights - Yahoo Finance
DNLI gains 25.4% year to date: Should you buy, sell or hold the stock? - MSN
D.A. Davidson & CO. Invests $1.77 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform - Seeking Alpha
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive? - Yahoo Finance
Precision Trading with Denali Therapeutics Inc. (DNLI) Risk Zones - Stock Traders Daily
Denali Therapeutics Inc. $DNLI Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.1%What's Next? - MarketBeat
Denali Therapeutics Reclaims DNL593 Rights After Takeda Collaboration Ends - HarianBasis.co
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in - Yahoo Finance
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Denali gains on FDA approval of lead asset - MSN
DNLI Stock Price, Quote & Chart | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - ChartMill
FDA clears Denali Therapeutics drug as first brain-penetrating biologic for rare disease - MSN
Denali Therapeutics dips after pricing $200M equity offering - MSN
B. Metzler seel. Sohn & Co. AG Makes New $1.84 Million Investment in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Wall Street Zen - MarketBeat
Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform - Yahoo Finance Singapore
Leerink Partners Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $35.00 - MarketBeat
Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches - BioSpace
Denali Therapeutics (DNLI) CMO restates 204,402-share insider stake in Form 3/A - Stock Titan
Form DEFA14A Denali Therapeutics Inc. - StreetInsider
[ARS] Denali Therapeutics Inc. SEC Filing - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) sets 2026 virtual meeting and pay vote - Stock Titan
Wedbush Cuts Price Target on Denali Therapeutics to $25 From $30, Keeps Outperform Rating - marketscreener.com
Denali Therapeutics (DNLI) CMO details 170,612-share equity stake in Form 3 - Stock Titan
Targeted therapies dominate March’s five NME approvals - BioWorld News
Denali (DNLI) Stock: Why Smart Money Likes It (Investor Interest) 2026-04-20Social Buy Zones - Cổng thông tin điện tử Tỉnh Sơn La
Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm) - BioSpace
Technical Reactions to DNLI Trends in Macro Strategies - Stock Traders Daily
DNLI Should I Buy - Intellectia AI
Why Denali Therapeutics (DNLI) Is Up 7.4% After Regaining Full Rights To DNL593 Collaboration - Sahm
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock? - TradingView
Hunter Syndrome Market to Surpass USD 1.2 Billion by 2036 | 15+ Emerging Therapies and 10+ Companies Driving Innovation, analyses DelveInsight - Barchart
DNLI.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Retail Surge: Can Denali Therapeutics Inc withstand a market correction2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Pullback Watch: Is Denali Therapeutics Inc stock suitable for long term investingQuarterly Trade Report & Smart Money Movement Tracker - baoquankhu1.vn
Denali Therapeutics Inc. $DNLI Shares Acquired by Baillie Gifford & Co. - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Recent Share Pullback And Pipeline Growth Expectations - Sahm
Pullback Watch: Can Denali Therapeutics Inc withstand a market correctionMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Retail Surge: What are analysts price targets for Denali Therapeutics IncPrice Action & Risk Controlled Swing Alerts - baoquankhu1.vn
Trading the Move, Not the Narrative: (DNLI) Edition - Stock Traders Daily
Q3 EPS Estimate for Denali Therapeutics Increased by Analyst - MarketBeat
How AVLAYAH’s Accelerated Approval and Takeda Exit Will Impact Denali Therapeutics (DNLI) Investors - Sahm
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):